Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib

被引：5

作者：

Wainberg, Zev A.

Shapiro, Geoffrey

Curigliano, Giuseppe

Kristeleit, Rebecca Sophie

Leong, Stephen

Alsina, Maria

Milella, Michele

Britten, Carolyn D.

Gelmon, Karen A.

Olszanski, Anthony J.

Vaishampayan, Ulka N.

Lopez-Martin, Jose A.

Kern, Kenneth Alan

Pierce, Kristen J.

Perea, Rachelle

Houk, Brett

Pathan, Nuzhat

Razak, Albiruni R.

机构：

[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Ist Europeo Oncol, Milan, Italy

[4] UCL, Inst Canc, London WC1E 6BT, England

[5] Univ Colorado, Canc Ctr, Aurora, CO USA

[6] Vall dHebron Univ Hosp, Barcelona, Spain

[7] Regina Elena Inst Canc Res, Rome, Italy

[8] Med Univ South Carolina, Dept Med, Hollings Canc Ctr, Charleston, SC 29425 USA

[9] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[10] Temple Hlth, Fox Chase Canc Ctr, Philadelphia, PA USA

[11] Karmanos Canc Inst, Detroit, MI USA

[12] 12 Octubre Univ Hosp & Res Inst, Madrid, Spain

[13] Pfizer Oncol, San Diego, CA USA

[14] Pfizer Oncol, Groton, CT USA

[15] Pfizer Worldwide Res & Dev, San Diego, CA USA

[16] Pfizer Oncol, La Jolla, CA USA

[17] Pfizer, San Diego, CA USA

[18] Princess Margaret Canc Ctr, Drug Dev Program, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.2566

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2566

引用

页数：2